Clinical Trials Browser

Locally Advanced Rectal Cancer

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Advanced Solid Tumour

Advanced Solid Tumor

Nasopharyngeal Carcinoma

Adenocarcinoma

Non Squamous Non-small Cell Lung Cancer

Nasopharyngeal Neoplasms

Lymphatic Metastasis

Nasopharyngeal Carcinoma

Gastric Cancer Peritoneal Metastases

Esophageal Neoplasms

Extensive Stage Lung Small Cell Cancer

Digestive System Neoplasms

Colonic Neoplasms

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Esophageal Neoplasms

Gastric Cancer Stage

Carcinoma, Non-Small-Cell Lung

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Lymphoma, Follicular

Esophageal Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Stomach Neoplasms

Advanced Non-small Cell Lung Cancer

Esophageal Neoplasms

SCLC, Extensive Stage

Nasopharyngeal Carcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

Esophageal Neoplasms

Rectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Hypersensitivity, Triple Negative Breast Neoplasms

Clinical Trials

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

KontRASt-R

TRIUNITE06

FMT-LUNG

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

MRD2START

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

IN10018 Combination Therapy in Previously-treated Solid Tumors

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

OSCC

SPRING

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation